Renal Division, Peking University First Hospital, Beijing, People's Republic of China.
Kidney Int. 2013 Aug;84(2):366-72. doi: 10.1038/ki.2013.55. Epub 2013 Feb 27.
In this study, we measured soluble urokinase receptor levels, a possible permeability factor, in the plasma of patients with primary focal segmental glomerulosclerosis (FSGS) and determined their association with clinical and pathological data in 74 patients with primary FSGS. Healthy donors and patients with minimal change disease, membranous nephropathy, and secondary FSGS were used as controls. The plasma-soluble urokinase receptor levels, measured by commercial ELISA kits, of patients with primary FSGS (median: 2923, interquartile range 2205-4360 pg/ml) were significantly higher than those of patients with minimal change disease (median 2050 pg/ml), membranous nephropathy (median 2029 pg/ml), and normal individuals (median 1739 pg/ml). There was no significant difference in plasma-soluble urokinase receptor levels between the 74 patients with primary and 14 patients with secondary FSGS. The soluble urokinase receptor levels increased in the order of tip variant, to a not otherwise specified variant and a cellular variant. The soluble urokinase receptor levels were significantly but negatively correlated with creatinine clearance at presentation but positively correlated with crescent formation in patients with primary FSGS. During follow-up, receptor levels decreased significantly in patients with complete remission. Thus, plasma-soluble urokinase receptor levels did not differentiate primary and secondary FSGS, and although significantly elevated in FSGS, they showed considerable overlap with other glomerular diseases.
在这项研究中,我们测量了原发性局灶节段性肾小球硬化症(FSGS)患者血浆中的可溶性尿激酶受体水平(一种可能的通透性因子),并确定了其与 74 例原发性 FSGS 患者的临床和病理数据的关系。健康供体和微小病变性肾病、膜性肾病和继发性 FSGS 患者被用作对照。使用商业 ELISA 试剂盒测量的原发性 FSGS 患者的血浆可溶性尿激酶受体水平(中位数:2923,四分位距 2205-4360 pg/ml)明显高于微小病变性肾病(中位数 2050 pg/ml)、膜性肾病(中位数 2029 pg/ml)和正常个体(中位数 1739 pg/ml)。74 例原发性 FSGS 患者与 14 例继发性 FSGS 患者的血浆可溶性尿激酶受体水平无显著差异。可溶性尿激酶受体水平按尖端变异、未特指变异和细胞变异的顺序增加。可溶性尿激酶受体水平与原发性 FSGS 患者就诊时的肌酐清除率呈显著负相关,但与新月体形成呈正相关。在随访期间,完全缓解的患者的受体水平显著下降。因此,血浆可溶性尿激酶受体水平不能区分原发性和继发性 FSGS,尽管在 FSGS 中显著升高,但与其他肾小球疾病有相当大的重叠。